Yhdysvallat - englanti - NLM (National Library of Medicine)

pyrock chemical - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic, hand sanitizer hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available. - in children less than 2 months of age - on open skin wounds stop use and ask a doctor if irritation or rash occurs. these may be signs of a serious condition.

Yhdysvallat - englanti - NLM (National Library of Medicine)

pyrock chemical - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic, hand sanitizer hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available. - in children less than 2 months of age - on open skin wounds stop use and ask a doctor if irritation or rash occurs. these may be signs of a serious condition.

Yhdysvallat - englanti - NLM (National Library of Medicine)

pyrock chemical - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic, hand sanitizer hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available. - in children less than 2 months of age - on open skin wounds stop use and ask a doctor if irritation or rash occurs. these may be signs of a serious condition.

Singapore - englanti - HSA (Health Sciences Authority)

merck pte. ltd. - follitropin alfa - injection, solution - 33.34 mcg - follitropin alfa 33.34 mcg

Yhdysvallat - englanti - NLM (National Library of Medicine)

curium us llc - gallium chloride ga-67 (unii: a04b19o2b0) (gallium cation ga-67 - unii:99t03j52w0) - gallium cation ga-67 2 mci in 1 ml - gallium citrate ga 67 injection may be useful to demonstrate the presence and extent of hodgkin's disease, lymphoma, and bronchogenic carcinoma. positive gallium ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. gallium citrate ga 67 injection may be useful as an aid in detecting some acute inflammatory lesions. none.

Yhdysvallat - englanti - NLM (National Library of Medicine)

par pharmaceutical, inc. - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 5 mg - oral olanzapine is indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see clinical studies (14.1)]. when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dislipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5)]. monotherapy — oral olanzapine is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clinical trials in adult patients with manic or mixed ep

Israel - englanti - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone furoate; umeclidinium as bromide; vilanterol as trifenatate - powder for inhalation pre-dispensed - vilanterol as trifenatate 22 mcg/inh; umeclidinium as bromide 55 mcg/inh; fluticasone furoate 92 mcg/inh - vilanterol, umeclidinium bromide and fluticasone furoate - asthmatrelegy ellipta 92/55/22 mcg is indicated for the maintenance treatment of asthma in patients aged 18 years and older.trelegy ellipta 92/55/22 mcg should be prescribed for patients who are not adequately controlled on maintenance asthma medication, such as an ics/laba.important limitations of use:trelegy ellipta 92/55/22 mcg is not indicated for the relief of acute asthma.copd (chronic obstructive pulmonary disease)trelegy ellipta 92/55/22 mcg is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.

Yhdysvallat - englanti - NLM (National Library of Medicine)

henkel corporation - aluminum zirconium octachlorohydrex gly (unii: p9d3yp29my) (aluminum zirconium octachlorohydrex gly - unii:p9d3yp29my) - antiperspirant • reduces underarm perspiration • extra effective

Israel - englanti - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone furoate; umeclidinium as bromide; vilanterol as trifenatate - powder for inhalation pre-dispensed - vilanterol as trifenatate 22 mcg/inh; umeclidinium as bromide 55 mcg/inh; fluticasone furoate 184 mcg/inh - vilanterol, umeclidinium bromide and fluticasone furoate - asthmatrelegy ellipta 184/55/22 mcg is indicated for the maintenance treatment of asthma in patients aged 18 years and older. trelegy ellipta 184/55/22 mcg should be prescribed for patients who are not adequately controlled on maintenance asthma medication, such as an ics/laba.important limitations of usetrelegy ellipta 184/55/22 mcg is not indicated for the relief of acute asthma.trelegy ellipta 184/55/22 mcg is not indicated for patients with copd.

Yhdysvallat - englanti - NLM (National Library of Medicine)

pai holdings, llc dba pai pharma - cefotetan disodium (unii: 0gxp746vxb) (cefotetan - unii:48spp0pa9q) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefotan® and other antibacterial drugs, cefotan® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.  when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefotan® (cefotetan for injection, usp) is indicated for the therapeutic treatment of the following infections when caused by susceptible strains of the designated organisms: urinary tract infections caused by e. coli , klebsiella spp (including k. pneumoniae ), proteus mirabilis , proteus vulgaris , providencia rettgeri , and morganella morganii . lower respiratory tract infections caused by streptococcus pneumoniae , staphylococcus aureus (methicillin susceptible), haemophilus influenza e, klebsiella species (including k. pneumoniae ), e. coli , proteus mirabilis , and serratia marcescens .* skin and skin structure infections due to staphylococcus aureus (methicillin-susceptible), staphylococcus epidermidis (methicillin susceptible), streptococcus pyogenes , streptococcus species, escherichia coli , klebsiella pneumoniae , peptococcus niger *, peptostreptococcus species. gynecologic infections caused by staphylococcus aureus (methicillin susceptible), staphylococcus epidermidis (methicillin susceptible, streptococcus species, streptococcus agalactiae , e. coli , proteus mirabilis , neisseria gonorrhoeae , bacteroides fragilis , prevotella melaninogenica bacteroides vulgatus , fusobacterium species*, and gram-positive anaerobic cocci (including peptococcus niger and peptostreptococcus species). cefotetan, like other cephalosporins, has no activity against chlamydia trachomatis. therefore, when cephalosporins are used in the treatment of pelvic inflammatory disease, and c. trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. intra-abdominal infections caused by e. coli , klebsiella species (including k. pneumoniae ), streptococcus species, bacteroides fragilis , prevotella melaninogenica , bacteroides vulgatus and clostridium species (other than clostridium difficile [see warnings])*. bone and joint infections caused by staphylococcus aureus (methicillin susceptible)*. * efficacy for this organism in this organ system was studied in fewer than ten infections in clinical studies specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to cefotetan. therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. in cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, it is possible to use cefotan® concomitantly with an aminoglycoside. cefotetan combinations with aminoglycosides have been shown to be synergistic in vitro against many enterobacteriaceae and also some other gram-negative bacteria. the dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. note : increases in serum creatinine have occurred when cefotan® was given alone. if cefotan® and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated. the preoperative administration of cefotan® may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures that are classified as clean contaminated or potentially contaminated (e.g., cesarean section, abdominal or vaginal hysterectomy, transurethral surgery, biliary tract surgery, and gastrointestinal surgery). if there are signs and symptoms of infection, specimens for culture should be obtained for identification of the causative organism so that appropriate therapeutic measures may be initiated. cefotan® is contraindicated in patients with a known allergy to the cephalosporin group of antibiotics and in those individuals who have experienced a cephalosporin associated hemolytic anemia.